In a move to narrow the company focus on prescription medicines, Pfizer has agreed to merge its off-patents drug business, Upjohn, with Mylan in a Reverse Morris Trust transaction. The all-stock deal gives Pfizer shareholders a controlling 57% of the combined new company, while Mylan shareholders will own the remaining 43%. The new pharmaceutical company will be renamed once the transaction has closed, which is expected in mid-2020.